Ulcerative Colitis and Liver Function Tests: The Connection

Abnormal liver function tests turn up in roughly 30 to 50 percent of people with ulcerative colitis at some point during their disease, making the liver one of the organs most commonly affected outside the colon. The causes range from harmless, self-resolving enzyme bumps during a flare to serious conditions like primary sclerosing cholangitis that can reshape treatment decisions. Understanding which pattern your blood work shows, and what the likely explanation is, matters far more than simply knowing the numbers are “off.”

How Often Liver Tests Come Back Abnormal in UC

If your gastroenterologist seems unsurprised by an irregular liver panel, there is a reason. One study of UC patients found abnormal liver function tests in about 40 percent of them, with the most common pattern being a hepatitis-type elevation, meaning the aminotransferases (ALT and AST) were the enzymes predominantly raised rather than markers of bile-duct obstruction.¹ Broader estimates put the lifetime occurrence somewhere between 30 and 50 percent of IBD patients overall.²

The reassuring part: the single most common explanation is a transient elevation that resolves on its own. In one cohort, transient elevations accounted for about 63 percent of all abnormal results. Fatty liver disease came next at roughly 11 percent, followed by primary sclerosing cholangitis at about 6 percent, and drug-related liver injury at a similar rate.¹ So most of the time, the bump in your enzymes is temporary and tied to active inflammation or a passing insult. The clinical challenge is distinguishing these benign blips from the minority of cases that signal something that needs its own treatment plan.

Primary Sclerosing Cholangitis

Primary sclerosing cholangitis, or PSC, is the liver condition most tightly linked to UC and the one your doctor is most concerned about ruling in or out when liver tests stay persistently abnormal. PSC causes progressive scarring and narrowing of the bile ducts inside and outside the liver, eventually leading to bile buildup, liver damage, and in some cases liver failure. About 3 to 8 percent of UC patients develop PSC, a figure considerably higher than in Crohn’s disease, where the prevalence sits between roughly 1 and 3.5 percent.³ PSC is by far the most common immune-mediated liver condition in IBD, presenting in up to 8 percent of patients and more frequently in UC than Crohn’s.⁴

The relationship runs both ways. Most people diagnosed with PSC turn out to have IBD when investigated, typically an extensive colitis pattern.⁵ That mutual association has led researchers to suspect the two diseases share underlying immune mechanisms rather than being accidental neighbors.

A Different Kind of Colitis

UC patients who also have PSC tend to have a recognizably different disease pattern compared to those with UC alone. Their colitis often spans the entire colon with a right-to-left gradient, meaning inflammation is worse on the right side. They are more likely to have rectal sparing (the rectum looks relatively normal on scope) and backwash ileitis, where inflammation extends slightly into the end of the small intestine.⁶⁷

Paradoxically, despite having more extensive colonic involvement, UC-PSC patients tend to have milder day-to-day symptoms. A multicenter U.S. study found that 93 percent of UC-PSC patients had extensive disease compared to 61 percent of those with UC alone, yet their clinical activity scores were lower. The catch: those same patients had higher rates of eventual colectomy (about 21 percent versus 10 percent).⁸ So the colon may feel quieter but still progresses in ways that ultimately require surgery more often. This is one reason surveillance colonoscopies remain critical even when symptoms seem mild.

Why the Gut and the Liver Talk to Each Other

The gut and liver are connected through the portal vein, which carries blood from the intestines directly to the liver. This anatomy alone makes the liver a first-line recipient of whatever the inflamed gut is producing. But the connection goes deeper than plumbing.

During active gut inflammation, immune cells called T cells are activated in the intestinal wall. Some of these become long-lived memory cells. Normally, molecules on intestinal blood vessels guide these T cells specifically to the gut and nowhere else. In people who develop PSC, however, the liver starts expressing those same gut-homing molecules on its own blood vessels. The result is that activated T cells, originally primed against intestinal targets, can latch onto the liver’s blood vessel walls, enter the liver tissue, and drive inflammation there. Critically, these memory T cells can persist in the liver even after the original gut inflammation has calmed down, which is why liver disease can progress independently of colitis activity.⁹ This “dual-homing” immune response explains one of the more frustrating clinical realities: getting UC under control does not necessarily stop PSC from progressing, and vice versa.

When UC Medications Cause the Liver Problem

Not every abnormal liver test in UC points to a disease process. Sometimes the medications used to treat the colitis are the culprit. Two drug classes deserve particular attention.

Thiopurines

Azathioprine and mercaptopurine, commonly used to maintain remission, cause drug-induced liver injury in an estimated 3.7 to 13.3 percent of patients. The injury can show up in several ways: a quiet rise in liver enzymes with no symptoms, acute cholestatic or mixed hepatitis, or, with longer use, damage to the tiny blood vessels inside the liver. The cholestatic form tends to occur within the first three months, while vascular damage can appear months to years later and is dose-related. Genetic variations in an enzyme called TPMT play a role; people whose bodies over-methylate thiopurines accumulate a metabolite that is toxic to the liver. In those cases, adding low-dose allopurinol while cutting the thiopurine dose can shift the metabolism toward safer territory.¹⁰

Biologic Therapies

Infliximab and other anti-TNF biologics can also raise liver enzymes, though the injury tends to be mild and temporary. A prospective study monitoring 163 patients for a year found elevated aminotransferases in about 16 percent and cholestatic changes in about 2.5 percent. The enzyme bumps most often appeared between the second and fifth infusion and were associated with longer disease duration, higher body mass index, and pre-existing fatty liver.¹¹ For most patients on biologics, routine liver panels catch these changes early, and the elevations resolve without needing to stop the drug.

Fatty Liver Disease and Fibrosis

Fatty liver is increasingly recognized as a significant cause of abnormal liver tests in UC, and it tends to get overshadowed by the focus on PSC. One pilot study found the prevalence of metabolic-associated steatotic liver disease among IBD patients to be about 18 percent on ultrasound.¹² The reasons are multifactorial: corticosteroid use drives fat deposition, chronic inflammation alters metabolism, and nutritional swings during flares contribute.

Beyond fat accumulation, there is growing evidence that IBD patients develop liver fibrosis at higher rates than the general population. A matched-control study using transient elastography (a non-invasive scan measuring liver stiffness) found that IBD patients had about three times the odds of significant fibrosis and over eight times the odds of advanced fibrosis compared to controls. Steatosis was also more common, affecting about 41 percent of the IBD group versus 28 percent of controls.¹³ These numbers suggest that even when PSC has been excluded, the liver deserves ongoing attention in UC patients.

How Doctors Investigate Abnormal Results

When liver tests come back abnormal in someone with UC, the first step is determining the injury pattern. A hepatocellular pattern, where ALT and AST dominate, points toward drug toxicity, fatty liver, autoimmune hepatitis, or viral hepatitis. A cholestatic pattern, where alkaline phosphatase and bilirubin are the main culprits, raises suspicion for PSC or bile-duct obstruction. A mixed pattern could be either.²

If PSC is suspected, magnetic resonance cholangiopancreatography (MRCP) is the go-to imaging test. It provides a detailed picture of the bile ducts without radiation or invasive procedures. Among patients with IBD who had elevated liver enzymes, MRCP showed abnormal findings in about 36 percent of cases, considerably higher than the 14 percent rate in the general population with elevated enzymes.¹⁴ That gap reflects just how much more likely IBD patients are to have a biliary explanation for their abnormal labs.

For assessing fibrosis, elastography (FibroScan) appears more reliable in IBD patients than blood-based scoring tools. The FIB-4 index, a calculation that combines age, platelet count, and liver enzymes, did not correlate with actual liver stiffness measured by elastography in IBD patients.¹⁵ The reason likely comes down to the fact that IBD itself can independently alter platelet counts and liver enzymes, muddying the formula. If fibrosis screening is needed, the scan is more trustworthy than the blood test.

Colorectal Cancer Risk When PSC and UC Overlap

One of the most clinically consequential aspects of having both PSC and UC is a substantially elevated risk of colorectal cancer. PSC alone raises the risk of several cancers, including bile-duct cancer, gallbladder cancer, and liver cancer.¹⁶ But the colorectal cancer risk is where the combination of PSC and IBD really compounds the danger.

A national cohort study found that IBD patients with PSC had a colorectal cancer incidence rate of 269 per 100,000, compared to 95 per 100,000 for IBD patients without PSC and 58 per 100,000 for the general population. For people diagnosed with IBD before age 20, the disparity was even more striking: those with PSC had roughly 75 times the colorectal cancer risk of the general population, compared to about 19 times for IBD patients without PSC.¹⁷ These numbers explain why gastroenterology guidelines recommend annual surveillance colonoscopy for UC patients with PSC, often starting from the time of PSC diagnosis rather than waiting the usual eight to ten years after UC onset.

Gallstones, Overlap Syndromes, and Other Less Common Causes

PSC and drug toxicity get most of the attention, but several other conditions can cause abnormal liver tests in UC.

Gallstones occur at higher rates in UC patients, particularly in those who are older, have diabetes or hypertension, or have been hospitalized multiple times for flares. A Korean cohort study found that three or more hospitalizations roughly quadrupled the risk of developing gallstones, suggesting repeated flares themselves contribute to stone formation.¹⁸ The mechanism is still debated. The colon plays a small role in reabsorbing bile acids, and when it is chronically inflamed or eventually removed, excess bile may precipitate into stones. Some studies have reported increased gallstone formation after colectomy for UC, reinforcing the idea that a damaged or absent colon alters bile handling.¹⁹

Autoimmune overlap syndromes are uncommon but worth knowing about. Some patients develop features of two autoimmune liver conditions simultaneously, such as PSC combined with autoimmune hepatitis. These overlap cases present a diagnostic puzzle because the liver biopsy and blood work show hallmarks of both diseases at once or in sequence.²⁰ Treatment usually involves immunosuppression for the autoimmune hepatitis component along with management of the PSC, though no therapy has been proven to alter PSC progression.

Total parenteral nutrition (TPN), sometimes needed during severe flares when the gut needs complete rest, can itself harm the liver. In UC patients receiving intravenous cyclosporin alongside TPN, the combination caused liver damage in about 63 percent of patients, roughly double the rate seen with TPN alone.²¹ This is primarily a concern during acute hospitalizations, but it underscores how multiple liver insults can stack up during a bad flare.

Children and Liver Test Abnormalities in UC

The breakdown of causes differs in children. While transient elevations and fatty liver dominate in adults, the most common reason for abnormal liver tests in pediatric IBD is immune-related liver disease, including PSC, autoimmune sclerosing cholangitis, and autoimmune hepatitis. Drug-induced liver injury still occurs but is less common as a proportion of cases.²² This means that when a child with UC has persistently abnormal liver enzymes, the threshold for investigating autoimmune and biliary causes should be lower than in an adult, where a wait-and-recheck approach is more often reasonable.

What Happens to UC After a Liver Transplant

For the small number of UC patients whose PSC progresses to end-stage liver disease, transplantation raises a natural question: does replacing the liver help or hurt the colitis? The answer is mostly encouraging. A study following UC-PSC patients through liver transplant found that colitis became quiescent in about 83 percent of them after the procedure. The rate of flares dropped from 0.16 per patient-year before transplant to 0.06 per patient-year afterward.²³ However, about 15 percent still required colectomy after transplant, so the improvement is not universal. The heavy immunosuppression required after transplant likely suppresses colitis activity, but it also introduces its own risks, including a higher baseline cancer risk that makes colonoscopic surveillance even more important.

PSC can also recur in the transplanted liver, though this typically happens years later and progresses slowly. The possibility of recurrence means that even after transplant, liver function tests remain a routine part of follow-up for these patients indefinitely.

Monitoring That Keeps Pace With the Disease

Given how many different things can push liver tests off-course in UC, routine monitoring is not optional. Most gastroenterologists check a liver panel at diagnosis and periodically afterward, especially when starting or adjusting medications. If alkaline phosphatase is persistently elevated, that is the clearest signal to investigate for PSC with MRCP. If aminotransferases climb after starting a thiopurine, metabolite levels can help determine whether a dose adjustment, a switch to allopurinol co-therapy, or a change in medication class is needed.

Elastography is gaining ground as a screening tool for fibrosis in IBD clinics, particularly since traditional blood-based fibrosis scores do not perform well in this population.¹⁵ The combination of a liver panel, MRCP when indicated, and periodic elastography gives clinicians a reasonably clear picture of what is happening without subjecting patients to frequent biopsies. For UC patients, the practical takeaway is straightforward: abnormal liver tests are common enough to expect, but never so routine that they should be brushed off without working out the cause.

1
PubMed. Prevalence and factors associated with the presence of abnormal function liver tests in patients with ulcerative colitis
2
PubMed Central. Hepatic Manifestations of Inflammatory Bowel Disease
3
PubMed Central. Ulcerative Colitis with and without Primary Sclerosing Cholangitis: Two Different Diseases?
4
PubMed Central. Liver-side of inflammatory bowel diseases: Hepatobiliary and drug-induced disorders
5
PubMed. Inflammatory bowel disease and primary sclerosing cholangitis: One disease or two?
6
PubMed Central. Primary sclerosing cholangitis and inflammatory bowel disease comorbidity: an update of the evidence
7
Gut and Liver. Inflammatory Bowel Disease and Primary Sclerosing Cholangitis: A Review of the Phenotype and Associated Specific Features
8
Inflammatory Bowel Diseases. Unique Phenotypic Characteristics and Clinical Course in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis: A Multicenter US Experience
9
Experimental & Molecular Medicine. Primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD): a condition exemplifying the crosstalk of the gut–liver axis
10
Journal of Crohn’s and Colitis. Drug-Induced Liver Injury Used in the Treatment of Inflammatory Bowel Disease – Section: 3. Thiopurines
11
Journal of Crohn’s and Colitis. Drug-Induced Liver Injury Used in the Treatment of Inflammatory Bowel Disease – Section: 5. Biological Therapy
12
PubMed Central. Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients with Inflammatory Bowel Diseases: A Pilot Study
13
PubMed. Liver Fibrosis and Steatosis in Inflammatory Bowel Disease: A Cross-Sectional Matched-Control Transient Elastography Study (ELASTIBD)
14
European Journal of Gastroenterology & Hepatology. The utility of magnetic resonance cholangiopancreatography for the assessment of patients with elevated liver enzyme levels
15
PubMed Central. Liver Fibrosis Index-4 Does Not Correlate to Liver Elastography in Patients with Inflammatory Bowel Disease
16
PubMed Central. Cancer surveillance in patients with primary sclerosing cholangitis
17
Clinical Gastroenterology and Hepatology. Impact of Inflammatory Bowel Disease and Primary Sclerosing Cholangitis on Colorectal Cancer Risk: National Cohort Study
18
PubMed Central. Gallstone prevalence and risk factors in patients with ulcerative colitis in Korean population
19
PubMed Central. Prevalence of Gallstones in Ulcerative Colitis and Crohn’s Disease: A Systematic Review and Meta-Analysis
20
PubMed Central. Ulcerative colitis complicated by primary sclerosing cholangitis and autoimmune hepatitis overlap syndrome: a case report and literature review
21
PubMed. Hepatotoxicity of intravenous cyclosporin A in patients with acute ulcerative colitis on total parenteral nutrition
22
PubMed Central. Managing abnormal liver tests in children with inflammatory bowel disease
23
PubMed. The effects of liver transplantation on the clinical course of colitis in ulcerative colitis patients with primary sclerosing cholangitis